Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
Emmanuele De Luca,1,2,* Donatella Marino,1,2,* Massimo Di Maio1,2 1Department of Oncology, University of Turin, Torino, Italy; 2Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy*These authors contributed equally to this workCorrespondence: Massimo Di MaioDivision of Medical Onc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-05-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/ramucirumab-a-second-line-option-for-patients-with-hepatocellular-carc-peer-reviewed-article-CMAR |